Investing in Brilliance: Denby Evans and the Future of Child Health

 

Every breakthrough begins with a question - and for Denby Evans, that question is: Can we stop lung disease before it starts?

 

Preterm birth is one of the most common and challenging problems in neonatal care. Babies born too early often struggle to breathe, and these difficulties can persist into childhood and even adulthood. Despite decades of progress, there are still no effective treatments to prevent the long-term lung damage caused by preterm birth.

 

Denby's research aims to change that. Her project, "The airway epithelium: A treatable trait of preterm lung disease?", funded through a Raine Priming Grant co-supported by Charter Hall and the BrightSpark Foundation, is tackling the problem at its source. Instead of just treating symptoms, Denby is investigating whether the airway lining - the epithelium - holds the key to preventing chronic lung disease. By studying airway cells from children born preterm and linking cell behaviour to breathing outcomes, her team hopes to identify new medicines that could transform care for thousands of vulnerable babies.

 

This is not just science - it's hope. And it's exactly why the Raine Foundation invests in the brightest minds at the earliest stages of their careers. Denby has also received a Raine Research Collaboration Award, enabling her to build partnerships and accelerate discovery. These grants are more than funding; they are a vote of confidence in ideas that can change lives.

 

As Dr Denby Evans says, her work is about "helping our smallest babies grow into healthy adults." With Raine Medical Research Foundation's support, that vision is closer than ever.

 

If you would like to support the Raine Medical Research Foundation, visit www.rainefoundation.org.au.